Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an announcement.
RemeGen Co., Ltd. has announced the renewal of several connected transactions, including the MabPlex Master Service Agreement and the Materials Purchase Framework Agreement, extending their terms from 2026 to 2028. These transactions, which involve key stakeholders such as MabPlex and RC Pharma, are crucial for the company’s continued operations and strategic partnerships. Additionally, the company plans to adjust its leasing agreements by increasing equipment leases and reducing building and apartment leases, reflecting its business expansion and changing demand.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$88.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating primarily in the biotechnology and pharmaceutical industry. The company focuses on developing and commercializing innovative therapies and products, with a significant emphasis on connected transactions within its operations.
Average Trading Volume: 7,627,887
Technical Sentiment Signal: Buy
Current Market Cap: HK$53.26B
For a thorough assessment of 9995 stock, go to TipRanks’ Stock Analysis page.